biostudies-literaturevon der Schulenburg PMarylyn Martina AddoJulian Schulze zur Wiesch339-351https://www.ebi.ac.uk/biostudies/studies/S-EPMC11017769biostudies-literatureUnknown12(3)<h4>Background</h4>In the third year of the SARS-CoV-2 pandemic, little is known about the vaccine- and infection-induced immune response in liver transplant recipients (LTR) and liver cirrhosis patients (LCP).<h4>Objective</h4>This cross-sectional study assessed the vaccination coverage, infection rate, and the resulting humoral and cellular SARS-CoV-2-specific immune responses in a cohort of LTR and LCP at the University Medical Center Hamburg-Eppendorf, Germany between March and May 2023.<h4>Methods</h4>Clinical and laboratory data from 244 consecutive patients (160 LTR and 84 LCP) were collected via chart review and a patient survey. Immune responses were determined via standard spike(S)- and nucleocapsid-protein serology and a spike-specific Interferon-gamma release assay (IGRA).<h4>RUnited European gastroenterology journalHigh vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study.PMC11017769SFB1328, project A12 and DZIFDZIFTTU 01709Harberts AJahnke-Triankowski JJorg VWehmeyer MPischke SHerting ADrolz ASchulze Zur Wiesch Jvon der Schulenburg PLutgehetmann MLohse AWSterneck MHubener PFischer LPiecha FAddo MMfalseHigh vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study.<h4>Background</h4>In the third year of the SARS-CoV-2 pandemic, little is known about the vaccine- and infection-induced immune response in liver transplant recipients (LTR) and liver cirrhosis patients (LCP).<h4>Objective</h4>This cross-sectional study assessed the vaccination coverage, infection rate, and the resulting humoral and cellular SARS-CoV-2-specific immune responses in a cohort of LTR and LCP at the University Medical Center Hamburg-Eppendorf, Germany between March and May 2023.<h4>Methods</h4>Clinical and laboratory data from 244 consecutive patients (160 LTR and 84 LCP) were collected via chart review and a patient survey. Immune responses were determined via standard spike(S)- and nucleocapsid-protein serology and a spike-specific Interferon-gamma release assay (IGRA).<h4>R2024-01-01T00:00:00Z2024 Apr2025-04-19T20:27:44.919Z2024-11-12T11:15:45.199ZS-EPMC110177693827983710.1002/ueg2.12528